Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT-Reference-Cited by-同舟云学术

Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT

Published:2017-06-20 Issue:15 Volume:1 Page:1056-1066
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Ho Christine M.¹,McCarthy Philip L.¹^ORCID,Wallace Paul K.²,Zhang Yali¹,Fora Ahmad¹,Mellors Patrick¹,Tario Joseph D.²,McCarthy Benjamin L. S.¹,Chen George L.¹,Holstein Sarah A.³,Balderman Sophia R.¹,Cao Xuefang⁴,Paiva Bruno⁵,Hahn Theresa¹

Affiliation:

1. Department of Medicine and

2. Department of Flow and Image Cytometry, Roswell Park Cancer Institute, Buffalo, NY;

3. Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE;

4. Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY; and

5. Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain

Abstract

Key Points Specific immune phenotypes were predictive of long-term survival for MM patients undergoing transplantation. MRD status and use of maintenance therapy were associated with unique immune profiles predictive of outcome.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/15/1056/878494/advances005447.pdf

Reference28 articles.

1. Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients;McCarthy;Hematology Am Soc Hematol Educ Program,2013

2. Lymphoid subsets and prognostic factors in multiple myeloma;San Miguel;Br J Haematol,1992

3. Complete response after autologous stem cell transplant in multiple myeloma;Kumar;Cancer Med,2014

4. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study;Ege;Br J Haematol,2008

5. T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93;Kay;Br J Haematol,1998

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prognostic value of combined CBC and immune cell profiles in patients with multiple myeloma treated with PAD sequential transplantation;2024-09-11

2. Outcomes of Human Leukocyte Antigen-Matched Related Donor and Haploidentical Allogeneic Hematopoietic Cell Transplantation Recipients by Immune Profiles of Recipients and Donors;Transplantation and Cellular Therapy;2024-08

3. Immune profiles to predict bortezomib-based treatment response for multiple myeloma patients;International Immunopharmacology;2024-03

4. Gamma Delta T Cells: A Prospective Analysis of Their Regeneration Kinetics and Their Impact on the Clinical Outcome Following Allogeneic Hematopoietic Stem Cell Transplantation;AlQalam Journal of Medical and Applied Sciences;2024-02-09

5. γδ T cells in immunotherapies for B-cell malignancies;Frontiers in Immunology;2023-06-22